



Quantitative and Textural Analysis of Magnetization
Transfer and Diffusion Images in the Early Detection
of Brain Metastases
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Purpose: The sensitivity of the magnetization transfer ratio
(MTR) and apparent diffusion coefficient (ADC) for early detec-
tion of brain metastases was investigated in mice and humans.
Methods: Mice underwent MRI twice weekly for up to 31 d fol-
lowing intracardiac injection of the brain-homing breast cancer
cell line MDA-MB231-BR. Patients with small cell lung cancer
underwent quarterly MRI for 1 year. MTR and ADC were meas-
ured in regions of metastasis and matched contralateral tissue
at the final time point and in registered regions at earlier time
points. Texture analysis and linear discriminant analysis were
performed to detect metastasis-containing slices.
Results: Compared with contralateral tissue, mouse metasta-
ses had significantly lower MTR and higher ADC at the final
time point. Some lesions were visible at earlier time points on
the MTR and ADC maps: 24% of these were not visible on
corresponding T2-weighted images. Texture analysis using the
MTR maps showed 100% specificity and 98% sensitivity for
metastasis at the final time point, with 77% sensitivity 2–4 d
earlier and 46% 5–8 d earlier. Only 2 of 16 patients developed
metastases, and their penultimate scans were normal.
Conclusions: Some brain metastases may be detected earlier
on MTR than conventional T2; however, the small gain is
unlikely to justify “predictive” MRI. Magn Reson Med
77:1987–1995, 2017. VC 2016 The Authors Magnetic Reso-
nance in Medicine published by Wiley Periodicals, Inc. on
behalf of International Society for Magnetic Resonance in
Medicine. This is an open access article under the terms
of the Creative Commons Attribution License, which per-
mits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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INTRODUCTION
Brain metastases (BM) develop in 20 to 40% of all cancer
patients and are a major cause of morbidity and mortal-
ity(1). Neurosurgery or stereotactic radiosurgery may be
possible in selected patients, but for the majority, treat-
ment options include steroids, whole brain radiotherapy,
and supportive care with median survival measured in a
small number of months. Cumulative incidence of brain
metastases is noted to be particularly high for patients
with locally advanced lung cancer and HER2 positive
metastatic breast cancer, with figures of up to 30–60%
reported (2–5). The high incidence of BM is perhaps the
result in part of the use of targeted drugs such as mono-
clonal antibodies: These are effective in controlling
extracranial metastatic disease and thereby extending
survival, but they do not cross the blood-brain barrier
and are therefore ineffective against BM.
In light of the very high incidence of BM for patients
with small cell lung cancer (SCLC), prophylactic cranial
irradiation (PCI) was introduced into the routine manage-
ment of patients with limited stage (2) and extensive stage
(3) disease, and it significantly improves overall survival
in addition to significantly reducing the incidence of BM.
There have also been a number of trials investigating the
role of PCI for non-small-cell lung cancer (NSCLC) (4),
which show significant reduction in the incidence of BM
but no significant difference in overall survival. Although
one recent small study of PCI for breast cancer (6) hinted
that PCI could reduce BM incidence at 2 years, it was
underpowered for statistical significance.
Although PCI is routinely used in patients with SCLC,
careful assessment of cognitive function does show a
decline in memory and recall with PCI in survivors (7),
and hippocampal sparing PCI may be helpful. Alternative
strategies for patients at high risk for developing brain
metastases from other primary sites, where PCI does not
improve overall survival, include careful follow-up with
MRI to detect BM before they are symptomatic and when
they might be most suitable for targeted treatment.
MRI is the gold standard for detection of brain metas-
tases, but it is not universally given to cancer patients
who lack neurological symptoms at presentation. Even
in patients with a normal MRI brain scan at diagnosis
and limited-stage SCLC, a recent study found that 32.5%
subsequently developed MRI evidence of brain metasta-
ses by the end of chemotherapy, before receiving PCI (5).
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If we could noninvasively identify any alteration in the
brain microenvironment that precedes the current clini-
cal detection of metastases, using techniques such as
magnetization transfer ratio (MTR) or apparent diffusion
coefficient (ADC), it may be possible to better individual-
ize treatment regimes and improve survival.
The MTR of primary brain tumors has been shown to
be reduced relative to normal brain in preclinical (8–10)
and clinical studies (11,12). In rat glioma models, the
MTR has been shown to fall further with the develop-
ment of the tumor (9). A small clinical study has shown
a reduction in MTR both within metastases and outside
of the contrast-enhanced region (13). Most of the clinical
brain metastases have increased ADC in comparison
with normal brain; however, reductions have also been
reported in highly cellular metastases such as in SCLC
(14,15).
Texture analysis (TA) is a method of mathematical clas-
sification of images based on the intensity variations
within them. A number of features can be calculated from
an image, based for example on spatial factors such as the
local gradient of intensity changes or co-occurrence of
similar intensities within a certain distance (16).
Histogram-based features from the entire image may also
be considered, as may higher-order features such as spa-
tial frequency distributions following wavelet transforma-
tions or fits to an autoregressive model (17).
Texture analysis has been evaluated as an automated
tool for classifying brain tumor types and grades: It has
been shown to have 100% accuracy in classifying benign
from malignant lesions and up to 94% accuracy in dis-
crimination of primary from secondary tumors (18). It
has also shown utility, when compared with qualitative
inspection of MRI, in automatic detection of more subtle
cortical abnormalities such as focal cortical dysplasia, a
malformation of cortical development that causes intrac-
table epilepsy (19). Although usually applied to conven-
tional MR images, it has also been applied to MTR
images to identify patients with multiple sclerosis (20),
and to ADC images to identify mild traumatic brain
injury (21).
The aim of this study was to explore the potential of
quantitative and textural analysis of serial MR imaging
to detect and predict the development of brain metasta-
ses. The study was primarily carried out in mice using a
brain-homing breast cancer cell line, but a small pilot




All animal experimentation was performed in accord-
ance with the UK Animals (Scientific Procedures) Act of
1986 and with local ethical approval under PPL 80/2203.
The brain-homing breast cancer cell line MDA-MB231-
BR (supplied by Prof. Joseph Frank at NIH laboratories,
Bethesda Maryland, with permission from Dr. Diane Pal-
meri at NIH) was delivered via intracardiac injection
into groups of no more than 10 female 6–7-week-old
SCID mice from Charles River Laboratories (inoculum of
105 cells in 100ml). Typical body weight was 15–19 g,
and remained static in mice developing metastases,
while the maximum weight gain seen in control (saline-
injected) mice was 2 g. The final health end point was
defined as the occurrence of limb weakness, seizures, or
20% weight loss.
Mice underwent MRI twice weekly from 14 d post-
intracardiac injection until the health end point previ-
ously defined; available magnet time typically allowed for
scanning on days 14 or 15, 17 or 18, 21 or 22, and 24 or
25 and some later times. The mean time from injection to
culling (the “final time point”) was 24 d (range 21–31;
Table 1). Eight control mice injected with DPBS were also
scanned on multiple occasions using the same scan proto-
col, with the final time point at day 21–24 and the early
time point at day 18–21. Mice that underwent intracardiac
injection of MDA-MB231-BR eGFP cells, but did not
develop metastases visible on the MR images or reach the
defined health end point, were kept and imaged for a fur-
ther 2–3 weeks. On completion of imaging, or earlier if
the animal became unwell, it was humanely killed by per-
fusion fixation under terminal inhalation anesthesia (2–
4% isoflurane in 100% oxygen) and the fixed brain was
paraffin-embedded for histological examination.
Preclinical MRI
Mice were positioned head first, prone in a 72-mm vol-
ume transmit coil with a quadrature brain receive coil
(Rapid Biomedical, W€urzburg, Germany) inside a 9.4
Tesla (T) Agilent MR scanner (Agilent Technologies,
Yarnton, Oxford, UK) equipped with a gradient set of
strength 40G/cm, 120msec rise time and 120-mm inner
diameter. Motion was minimized using custom-made
padding, securing the limbs and tail, and using tooth
and ear bars when feasible. Animals were anesthetized
using inhaled isoflurane (Abbotts Laboratories, Berk-
shire, UK). Isoflurane was delivered in oxygen (1L/min)
at 2–3% for induction and 1.5–2% for maintenance as
required. Excess gases were scavenged (Active Scaveng-
ing Unit, Vet Tech Solutions, Cheshire, UK). Core tem-
perature and respiration rate were monitored using a
Small Animal Instruments monitoring/control system
(SA Instruments, New York, New York). The core body
temperature was monitored using a rectal probe, and
was maintained at 36.8 C by warm air blown over the
animal. Respiration rate was measured using a respira-
tory pillow taped to the mouse’s abdomen and attached
to a pressure transducer. The respiratory rate was
recorded and maintained at 50–110 breaths per minute
by adjustment of the level of anesthesia.
The brain was shimmed manually on the free induc-
tion decay (FID) to achieve a line width of <75Hz. T2-
weighted fast spin echo localizers were acquired in the
Table 1








Mean6SD 24.563.7 3.06 0.6 6.06 1.2
Range 21–32 2–4 5–8
N (mice) 12 11 10
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axial plane (echo time (TE)/pulse repetition (TR)¼ 48/
2000 ms, 128 128, field of view (FOV) 20mm, chemical
shift selective (CHESS) fat saturation, 15 slices, 0.5-mm
thick, 0.2-mm gap, interleaved, echo train length (ETL)
8, echo spacing 12 ms, 8 averages). Coronal slices were
prescribed using anatomical landmarks on the central
axial slice in matching locations for high-resolution T2
(TE/TR¼ 35/2000 ms, 160 160, 25-mm FOV, 15 inter-
leaved slices, 0.3-mm thick, 0.1mm gap); diffusion-
weighted echo planar imaging (EPI) (TE/TR¼ 23.9/2000
ms, 24 shots, ETL 6, 4 averages, 128128, 25-mm FOV,
15 slices, thickness 0.3mm, gap 0.1mm, acquiring one
image with minimal diffusion weighting (b¼ 22.4 s/
mm2) and three with b¼489 s/mm2 and diffusion gra-
dients oriented along each of the three orthogonal gradi-
ent axes); and magnetization transfer (three-dimensional
(3D) gradient echo with narrow-band off resonance
pulses with flip angles of 1350  and 400  and frequency
offsets of 4000 and 80000Hz, respectively, for magnetic
transfer (MT) on/off, TR 30 ms, 10  flip angle,
128 128 32 points, 25 2512.8mm FOV, slab thick-
ness 11mm, 8 averages). All images were reconstructed
to 256 256 resolution in plane, and trace (ADC) images
were calculated using software provided by the manufac-
turer. The MRI protocol took 2–2.5h per mouse, depend-
ing on the time taken to anesthetize and shim the mouse
before scanning. We chose to use similar spatial resolu-
tions for each sequence, so that partial volume effects
with small metastases would be similar. With this con-
straint, signal-to-noise ratio (SNR) and restrictions on
anesthesia duration prevented the use of enough gradient
directions for a full diffusion tensor imaging experiment;
we instead acquired three orthogonal directions, enough
to compute the trace of the diffusion tensor.
Preclinical MRI Analysis
Preclinical MR images were analyzed using ImageJ (v1.5;
National Institutes of Health, Bethesda, Maryland) and
locally developed plugins. MTR images were calculated
after thresholding according to
MTR ¼ 100M0 Ms
M0
[1]
where M0 is the image with the low-power high-offset
saturation pulse, and the Ms is the image with the high-
power low-offset pulse.
Brain extraction was performed on the T2-weighted
images using a freely available 3D pulse-coupled neural
network (PCNN) program (22,23) implemented in MAT-
LAB (Math Works, Natick, Massachusetts) with in-house
modification and a manually selected cutoff for edge
delineation. The brain mask was then applied to the
diffusion-weighted images (DWI) and MTR images in
MATLAB.
The skull-stripped 3D volumes from each of the early
time points of the T2-weighted images were independ-
ently registered to the final time-point images using
ANTS (Advanced Neuroimaging Tools) (24), which uses
a linear transform derived from a mutual information
similarity metric. The affine and warp transforms calcu-
lated were applied to both the T2-weighted and ADC
images from early time points to spatially align them
with the final time point. Because the MTR images have
inverted contrast relative to the T2-weighted images, they
were registered separately following the same method.
ROIs were drawn in ImageJ around metastases at the
final time point and at matched contralateral locations.
To maximize lesion visibility, ROIs were drawn on
images of ADC divided by MTR, then applied to the
individual parameter maps of MTR and ADC (Fig. 1).
Descriptive statistics for each region of interest (ROI)
(mean, standard deviation (SD), median, and diameter)
were recorded for the MTR and ADC images at the final
time point and at all earlier time points, which had been
registered as described previously. ROI analysis results
were analyzed using Microsoft Excel (Microsoft, Reading,
UK) and GraphPad Prism (version 6.00 for Windows,
GraphPad Software, La Jolla, California).
Texture Analysis
The maps of MTR, ADC, and ADC/MTR were converted
to 16-bit integer data, scaled such that the full integer
range corresponded to the range 0–1 in the original MTR
map and ADC/MTR images, and 0–0.004 for ADC. Slices
7 to 13 from the top of the standard 15-slice data set
were analyzed, as these slices all contained metastases
in the metastasis-positive mice. Control data consisted of
the same slices from the sham-injected mice. Any appa-
rent imperfections in the skull-stripped brain masks
were corrected using a combination of thresholding and
erosion in ImageJ, followed by manual dilation of the bit-
mask in MaZda version 4.6 (Institute of Electronics,
Technical University of Lodz, Poland) (17).
FIG. 1. Example of ROI definition in mouse MRI at the final time point. MTR map (a), ADC map (b), map of ADC divided by MTR, to
maximize conspicuity of lesions (c), ROIs defined (metastases are shown in red and matched contralateral brain in blue) (d).
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In MaZda, the image intensities were normalized to
the mean 63 SD, and the full set of over 300 texture
parameter values were calculated for each slice. The top
30 features that differed most significantly between
metastasis and control slices acquired at the final time
point (training set) were selected using the Fisher, mini-
mization of classification error probability and average
correlation coefficients (POEþACC), and mutual informa-
tion (MI) methods within MaZda. Following this feature
reduction, linear discriminant analysis (LDA) was per-
formed using b11, the statistical package within MaZda,
on the images from metastasis and control mice to opti-
mize the separation of the classes, as visualized by plot-
ting the MDF-1 (the first most discriminating feature)
(25) in GraphPad Prism.
MTR maps from both control and metastasis-positive
mice acquired at earlier time points (the penultimate
time point, “early metastases” and “early control”, and
for metastasis-positive mice at the time point before,
“very early metastases”) were also evaluated using tex-
ture analysis (the test sets). The MDF-1 was calculated
using the same top 30 features, weightings, and formulas
optimized for the training group.
Clinical MRI
The study protocol was approved by the Cambridge
Research Ethics Committee and all subjects provided
written, informed consent. Patients with a histological
diagnosis of SCLC with no contraindications for MRI
were studied on four occasions (at diagnosis, post-
chemotherapy at approximately 4 months, post-PCI at 8
months, and at 1 year) on a 3T HDx scanner using body
coil transmission and an eight-channel phased-array
head coil (GE Healthcare, Waukesha Wisconsin). The
protocol included the following, all acquired in the axial
plane: T2-weighted fast spin echo (TE/TR¼ 98.7/7000
ms, ETL 32, FOV 22cm, matrix 512 384, ASSET accel-
eration factor 2, slice thickness of 5mm with 1-mm gap),
fluid-attenuated inversion recovery (FLAIR) (TE/TI/
TR¼ 121.7/2000/7000 ms, FOV 22 cm, matrix 384 224,
slice thickness 5mm, 1-mm gap), single-shot EPI spin
echo diffusion tensor imaging (23 slices, 5-mm thick, 1-
mm gap, ASSET factor 2, TE/TR¼ 76.8/6000 ms, FOV
22 cm, matrix 128 128, b values of 0 and 1000 s/mm2
along 25 gradient directions), magnetization transfer
using a 3D fast spoiled gradient echo (FSPGR) (TE/
TR¼ 1.1/28.5 ms, FOV 22 cm, matrix 256 160,
603mm slices, 8 ms Fermi MT pulse with frequency
offset 2200Hz and a nominal flip angle of 450 ), pre-
and postgadolinium T1-weighted FSPGR (TE/TI/
TR¼ 3.9/450/9.5 ms, flip angle 20o, bandwidth 31.25
kHz, FOV 22 cm, matrix 352 224, ASSET factor 2,
120 1.2mm slices, Gadopentetate dimeglumine (Gd-
DTPA) delivered via an intravenous bolus of 0.1 mmol/
kg). Maps of ADC and FA were computed by the scanner
software, and MTR maps were computed offline using
scripts in FSL (FMRIB Lab, Oxford, UK).
RESULTS
Preclinical MRI
Of the 29 mice injected with MDA-MB231-BR cells and
scanned on multiple occasions, 14 developed brain
metastases (48%). Four of these did not have diffusion
data collected as a result of technical problems early in
the study. For the 10 mice with the full MRI protocol
acquired, the mean number of brain metastases observed
was 32 (range 13–53). Because the metastases often
spanned multiple slices, the average number of ROIs
drawn was 44 (range 13–158), with average diameter
0.8mm (range 0.5–1.7).
Quantitative analysis of MTR and ADC at the final
time point showed significant differences on paired t-
tests between the metastases and ROIs at matched con-
tralateral locations (Table 2; Fig. 2): The metastases had
lower MTR and higher ADC (P< 0.0001 for both). The
use of paired ROIs is helpful, as the parameters can vary
in different parts of the brain. MTR in particular is
FIG. 2. Paired values of MTR (a) and ADC (b) in metastasis and
contralateral ROIs. For each, P<0.0001 in paired t-tests.
Table 2
Summary Statistics for Parameters Measured in ROIs Drawn in
Metastases and Matching Contralateral Locations in Mouse Brain
at the Final MRI Time Point Prior to Culling.
MTR (%) ADC (103 mm2/s)
Metastasis 51.46 3.2 0.936 0.13
Contralateral 55.36 2.5 0.716 0.08
Paired difference 3.86 2.9 0.226 0.13
t-statistic 25.9 32.8
N 381 357
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known to be higher in white matter than gray (26). The
ratio of metastasis to contralateral regions was plotted for
each parameter measured in serially registered images
from the same mice over time (Fig. 3), showing that
although there was variation in the lag before changes
were measurable, once initiated, the rate of decrease in
MTR and increase in ADC was consistent among ani-
mals. There was a significant negative correlation
between MTR and ADC in metastasis voxels but not in
contralateral normal-appearing brain (Fig. 4).
Metastases were seen in most mice at approximately
day 21, with some detectable at day 18. All of the
metastases visible on the T2-weighted images were also
identified on the MTR and/or the ADC images; how-
ever, in 24% of the cases, metastases could be seen on
the MTR and ADC images but not on the T2-weighted
ones. For example, Figure 5 shows a metastasis that was
visible on ADC and MTR images but not on the T2-
weighted image (long arrows). This same metastasis can
be seen in the MTR and ADC images at day 18 as well.
The diameter of this metastasis (measured in ImageJ on
the MTR image) was 0.37mm, larger than the metastasis
highlighted by the short arrow, which is clearly seen on
all images (0.30mm), so the invisibility on T2 is not
solely due to size—particularly because the T2-weighted
images were acquired at the highest spatial resolution
(in-plane pixel diameter 0.16mm, versus 0.20 for DWI
and MTR).
Texture Analysis
Comparison of the MRI scans with histology showed that
MRI underestimated the size of visible lesions and failed
to detect many smaller lesions (data not shown). There-
fore, we investigated whether the sensitivity to abnor-
mality could be enhanced by performing texture
analysis, examining separately the maps of MTR, ADC,
and the ratio ADC/MTR. The best texture analysis classi-
fication of final time-point slices into metastasis versus
control was found when using MTR data alone (Fig. 6;
100% specificity, 98% sensitivity).
We then examined whether slices from the same mice
at earlier time points could also be classified as metasta-
sis or control using the MDF-1 calculated from the MTR
map texture parameters with the same formula as the
final time-point training set. At the early time point (2–4
d before culling), the sensitivity for identifying an image
slice as containing metastases was 77%, with 92% speci-
ficity (Fig. 7). At the very early time point (5–8 d before
culling), sensitivity was only 46% and specificity 79%.
Taking the mean MDF-1 over all slices for each mouse, 9
of 11 (82%) would be classified as abnormal at the early
time point, and 4 of 10 (40%) at the very early time
point.
FIG. 3. Time course of the ratios of values in metastases divided
by those in the matched contralateral ROIs for MTR (a) and ADC
(b). All time points were registered to the final images acquired for
that animal prior to culling at day 21–32.
FIG. 4. Correlation between the mean MTR and the mean ADC in
ROIs drawn in metastases (top, red) and contralateral brain (bot-
tom, blue). A significant negative correlation is found when there
is a metastasis present, but not in normal-appearing brain.
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Patient Details
Sixteen patients consented to the CLUB-01 trial: The
mean subject age was 65 (range 51–78 years), and 63%
were male. None were found to have metastases at diagno-
sis, and only two (12.5%) developed brain metastases over
the course of the study, considerably fewer than the inci-
dence reported in other trials (2,4,27,28). One of these
(Patient 9) had asymptomatic metastases detected at the
final scan (four lesions, mean diameter 5.4mm, range 3.4–
7mm), whereas the other (Patient 10) developed neurolog-
ical symptoms after four cycles of chemotherapy and was
found on CT to have six metastases (mean diameter
4.8mm, range 2.3–7mm). None of these metastases were
associated with edema. The time interval between the
final and penultimate scans was 4 months and 12 d for
Patient 10 and 3 months and 10 d for Patient 9 (and con-
trast was refused at the penultimate scan for Patient 9).
Patient MRI
Because there were only two cases of metastasis develop-
ment, no meaningful statistical comparisons could be per-
formed; however, the imaging findings are of interest.
Metastases were generally invisible on ADC maps but
could be seen as areas of reduced signal on maps of MTR
and FA at the final time point (Fig. 8). No abnormalities
were detected on the penultimate scan (data not shown).
DISCUSSION
The aim of this project was to optimize early detection of
cerebral metastases using quantitative MTR and ADC
imaging techniques, in combination with textural analysis
(TA) and other image processing techniques. The strategy
was biweekly sequential imaging of brains of mice
injected with the MDA-MB231-BR cell line, before and
after the development of visible metastases. Once the
metastases were seen, we examined the same regions on
earlier scans to see whether there were subtle changes that
could be visualized using our methods (as a result of, for
instance, the establishment of premetastatic niches (29)).
We found, as expected, a fall in the metastasis to contra-
lateral ratio of MTR and a rise in the corresponding ADC
ratio (Fig. 3); however, these ratios did not differ signifi-
cantly from 1.0 until the last 2–3 time points, when metas-
tases began to be visible in the images. Although
ultimately the magnitude of change in this ratio was
greater for ADC than for MTR, the shape of the curves was
more consistent for MTR, potentially allowing earlier
identification of developing abnormality. For ADC, appa-
rent early increases were often followed by levelling off or
FIG. 5. T2-weighted (left), MTR (middle),
and ADC (right) images from the same
mouse at three different time points (days
16, 18, and 21). Some lesions (long arrow)
can be seen on the MTR and ADC image
but not the T2-weighted images.
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decreases, indicative of variability in the pattern of devel-
opment and/or of imprecision in the measurement
procedure.
There was a significant negative correlation between
MTR and ADC within ROIs drawn in lesions, but not in
normal-appearing brain (Fig. 4). In a rat metastasis model
using the same cell line (30), tumors were found to have
elevated ADC, which corresponded to the extensive
edema seen on histology. The ADC increased further as
the tumors grew. Magnetization transfer has not previ-
ously been studied in this model, but reduced MTR has
been seen previously in rat glioma models (4,8,9,31) as
well as in clinical brain metastases (13). A recent study
investigated the development of brain metastases
induced by intracerebral injection of ENU1564 cells in
rats, using multimodal MRI. In keeping with our data,
they found that the MTR was the most sensitive measure
of micrometastatic growth, with a reduction in MTR evi-
dent as early as 7 d postinjection (32).
FIG. 6. Most discriminating feature (MDF-1) for classification of
image slices from the final time point as control (blue) versus
metastasis (red) based on texture analysis, for ADC (a), the com-
bined ratio ADC/MTR (b), and MTR (c). The dotted line is drawn at
the point of 100% sensitivity for detecting metastases.
FIG. 7. Classification of early and very early time-point data as
metastasis versus control using texture analysis of MTR maps.
Bars indicate the mean61 SD of the MDF-1 value for each
group, and the dotted line indicates MDF-1¼0.0001112, the
100% specificity threshold determined on the training set from the
final time point (left two columns, also shown in Fig. 6). The MDF-
1 value correctly classifies 58 of 63 slices from early controls and
59 of 77 slices from early metastasis, but only 22 of 28 from very
early controls and 32 of 70 slices from very early metastasis.
FIG. 8. Anatomic images and parameter maps acquired following
the development of neurological symptoms in Patient 10. Metasta-
sis is seen in the brainstem in T1-weighted images post-Gd (a),
T2-weighted images (b), MTR maps (c), and FA maps (d), but not
in ADC maps (e).
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The edema seen in this model, associated with an
increase in the free water content, would be expected to
decrease MTR as well as to increase water diffusion.
Additionally, myelin is thought to be a major contributor
both to the MT effect (33,34) and to the restriction of
water diffusion across axons (35), so the displacement or
replacement of myelinated axons by proliferating tumor
cells would be expected also to decrease MTR and
increase ADC in parallel.
In some cases, the changes in MTR and/or ADC pre-
ceded the appearance of a detectable metastasis on T2-
weighted imaging (Fig. 5). However, in the mouse model,
this increased the window of detectability by at most a
few days, and only for a subset of lesions (approximately
24%). We did not systematically evaluate lesion detect-
ability using Gd contrast agents, as our preliminary
experiments confirmed the findings of other groups that
blood brain barrier permeability is limited in these small
metastases, which co-opt host blood vessels with an
intact blood-brain barrier for their blood supply (30).
Phase contrast imaging has been suggested to perhaps be
more sensitive than dynamic contrast enhanced (DCE)
MRI as an early indicator of vascular remodeling during
metastasis development (36).
Texture analysis of mouse brain MTR maps was able to
classify images as metastatic or control, both on a training
set of final time-point data and on a test set of images from
2–4 d earlier. Although TA could detect metastases when
they were small and asymptomatic, it was unable to reli-
ably recognize any subtle alterations in the brain preced-
ing the appearance of metastases on the images.
Early metastases in patients showed reductions in
MTR similar to the animal model; however, ADC did not
increase, perhaps as a result of the lack of edema or mac-
roscopic necrosis associated with these small metastases
(Fig. 8). Studies correlating ADC with histology have
demonstrated that the ADC increased in areas of necrosis
but not in areas of viable tumor in mice with squamous
cell tumors (37), in rat gliomas (8), and in clinical brain
metastases (38). The lack of change in the ADC in small
tumors in the CLUB-01 patients suggests that they had
not yet outgrown their blood supply sufficiently to
become necrotic. The degree of cellularity and differen-
tiation may also affect ADC values: highly cellular and
poorly differentiated tumors have been found to have a
lower ADC then less cellular and better differentiated
tumors (14,15). Brain metastases from patients with lung
cancer may have particularly low ADC: Hayashida et al
(15) reported a lower ADC in SCLC brain metastases
(1.19 103 mm2/s) than even poorly differentiated
adenocarcinomas (1.40 103 mm2/s).
Although the changes in ADC were more equivocal in
humans than in mice, reductions in FA were striking.
We were unable to measure FA in the mouse model
because of SNR and examination time limitations, but it
seems likely that FA and MTR would be sensitive to
early metastasis development, because they are high (in
the case of MTR, uniformly high) in normal white mat-
ter, and are markedly reduced in metastases regardless of
the presence or absence of edema. Gaps in normal white
matter may perhaps be detectable earlier than the pres-
ence of abnormal cancerous cells using these techniques.
We were unable to detect any abnormalities on the
penultimate scan in the patients studied. The interscan
interval of over 3 months was long, but more frequent
scanning would be impracticable: if a predictive MRI
test were to be useful, it would need to detect metastases
that would first appear on conventional imaging a few
months after the screening date.
More significant improvements in early detection of
metastases have been shown using cell labeling: micro-
particles of iron oxide (MPIOs) allow direct monitoring
with MRI of single cells when injected into preclinical
models. The labeled cells are seen as hypo-intense vox-
els on T2-weighted or T

2-weighted images. Heyn et al
(39) have used this model to evaluate the formation of
brain metastases from single MDA-MB231-BR cells at
1.5T. Song et al (40) used a rat model to evaluate the
MDA-MB231-BR cell line transfected with luciferase,
and labeled with ferumoxides-protamine sulphate
(FEPro). Using T2-weighted MRI imaging, they could
identify micrometastatic tumors 2 weeks after injection.
In clinical studies it is not possible to label the tumor
cells directly with MPIOs to allow easier MRI evaluation.
Another approach, which could be applied in the clini-
cal setting, is to conjugate the MPIO to targeted ligands,
allowing the MPIOs to accumulate in areas where spe-
cific molecules are expressed. MPIOs have been conju-
gated to anti-VCAM1 antibodies (vascular cell adhesion
molecule 1), which were injected into mice that had also
received intracardiac injection of MDA-MB231-BR cells.
This process allowed MRI visualization of any up-
regulation of VCAM expression related to the brain
metastases (41). Early up-regulation of VCAM1 was
found in vessels related to micrometastases, with expres-
sion increasing with tumor growth. This up-regulation
allowed detection of the metastases 5 d after injection.
The authors discuss the translation to clinical studies;
however, the currently available MPIOs are nondegrad-
able, and therefore not suitable for use in patient studies.
CONCLUSIONS
This study shows some evidence that a subset of brain
metastases may be visualized on MTR and DWI earlier
than on T2-weighted imaging. The small expansion of the
window of detectability, albeit in a rapidly growing model
system, is unlikely to justify “predictive” MRI scanning.
However, screening with brain MRI at diagnosis might be
useful in management of small-cell lung cancer, and this
is not yet current practice across Europe.
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